VGXI Joins US Government's Rapid Response Partnership Vehicle

VGXI, Inc., a prominent contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, has been selected as a member of the Rapid Response Partnership Vehicle (RRPV). This initiative supports the Biomedical Advanced Research and Development Authority (BARDA) in expediting the development of Medical Countermeasure (MCM) products and technologies. These efforts aim to address critical needs such as pandemic influenza, emerging infectious diseases, and other biological threats.

Founded over two decades ago, VGXI boasts the world's largest plasmid DNA manufacturing capacity, with a total of 4000L across its two cutting-edge facilities spanning 160,000 square feet. The company's extensive experience includes the manufacture of vaccines for diseases like Influenza, Ebola, MERS, and COVID-19.

Young Park, VGXI's CEO, expressed pride in joining the RRPV, highlighting the company's role in global vaccine production. He emphasized VGXI's readiness to support RRPV members and U.S. Government partners in safeguarding the nation from future pandemics. Park also extended an invitation for partnerships in nucleic acid-based manufacturing, offering comprehensive solutions under one roof.

VGXI, Inc. has built a strong reputation over the years for its plasmid DNA manufacturing and development services. The company is known for producing DNA products under cGMP conditions for clinical trials across the U.S., EU, Asia, Canada, and Australia. VGXI's products have undergone stringent reviews by various international regulatory agencies, demonstrating their quality and reliability.

The company's success can be attributed to its patented manufacturing process, adaptable cGMP production facilities, and a highly skilled development team. VGXI is a subsidiary of GeneOne Life Science, a leading biotechnology company headquartered in Seoul, South Korea. GeneOne specializes in DNA plasmid manufacturing for vaccines, gene therapies, and cell therapies, with a recent expansion into mRNA production.

GeneOne has prioritized vaccine development for emerging infectious diseases, especially in resource-limited regions. The company's small molecule portfolio targets diseases such as upper respiratory bacterial and viral infections, as well as autoimmune and inflammatory diseases. GeneOne currently has three COVID-19 products in clinical development: GLS-5310 DNA vaccine (Phase I/IIa), GLS-1200 nasal spray to prevent COVID-19 infection (Phase II), and GLS-1027 to mitigate inflammation and clinical deterioration in COVID-19 patients (Phase II).

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!